Reacción a "Reactions: Spanish researchers propose new genetic form of Alzheimer's disease"

An important point to note is that: 
1. Monoclonal antibodies to beta-amyloid generate a large number of adverse effects in these patients, making it difficult to determine the benefit/risk balance. 

2. There are molecules in development specifically for the ApoE 4/4 population; a phase 3 clinical trial is currently underway with results due by the end of 2024.